Electrophysiological Markers of Chemotherapy-Induced Polyneuropathy
Introduction. Electrophysiological testing is the gold standard for diagnosing polyneuropathy. However, its use in oncology practice for patients with chemotherapy-induced polyneuropathy (CIPN) remains limited and the value of its findings is not fully understood. The study was aimed at identifyi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2025-06-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/pathID/article/viewFile/1283/pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. Electrophysiological testing is the gold standard for diagnosing polyneuropathy. However, its use in oncology practice for patients with chemotherapy-induced polyneuropathy (CIPN) remains limited and the value of its findings is not fully understood.
The study was aimed at identifying electrophysiological CIPN markers and evaluting their sensitivity and specificity.
Materials and methods. The study included patients (n = 71) over 18 years of age with solid tumor presenting with polyneuritic complaints following neurotoxic therapy with platinum-based agents and taxanes. Patients with known risk factors for polyneuropathy were excluded. Electrophysiological and clinical patient data were evaluated no earlier than 3 months following chemotherapy initiation.
Results. The study identified electromyographic markers: SRAR index (sural/radial ratio — the ratio between the action potential amplitudes of the sural and radial nerves) and the sural nerve action potential (SNAP), demonstrating equal sensitivity (73.7%) and high specificity (75% and 84.6%, respectively).
Conclusion. Electromyographic parameters such as SRAR and SNAP sural nerve can be utilized for the diagnosis and monitoring of CIPN in daily practice. |
|---|---|
| ISSN: | 2075-5473 2409-2533 |